Articles tagged with Pancreatic Cancer
A novel exosome-based liquid biopsy approach has been developed to detect pancreatic cancer at early stages. The method combines eight microRNAs uniquely found in exosomes shed from pancreatic cancers with five cell-free DNA markers, achieving a 97% detection rate for stage 1-2 cases.
Researchers found that an individualized neoantigen-specific mRNA vaccine, autogene cevumeran, can induce a robust immune response in patients with resectable pancreatic cancer. After a median follow-up of three years, the treatment was associated with a significantly longer median recurrence-free survival compared to those who did not...
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
Cold Spring Harbor Laboratory researchers developed Accelerated SuFEx Click Chemistry to create over 150 new molecular compounds, including derivatives of complex natural molecules. These compounds show promise as leads for developing antibiotics and cancer therapies.
Researchers at the University of Oklahoma have discovered how pancreatic cancer cells exploit an acidic environment to their advantage, finding ways to survive and grow. This knowledge is crucial for developing new therapeutic approaches to target the cancer.
Researchers at Mass General Cancer Center presented advancements in rapid nucleic acid detection for cervical cancer screening using CRISPR technology. They also showcased improvements to CAR T cell therapy for pancreatic cancer, highlighting the importance of dynamic functional control to enhance its efficacy.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
Researchers at VUB discovered that targeting the xCT protein can reduce tumour growth while regulating inflammation and improving mood. This finding holds promise for a comprehensive approach to treating pancreatic cancer, a highly malignant form of the disease.
Research reveals a significant connection between oral bacteria and accelerated pancreatic cancer development in mice. Viable Porphyromonas gingivalis was found in the pancreas of healthy mice after gum application, causing changes in the organ's microbial balance.
A study published in Lancet Gastroenterology & Hepatology found that not placing a drain during distal pancreatectomy surgery improves patient outcomes. The study, involving 282 patients across ten Dutch and two Italian hospitals, demonstrated a significant reduction in postoperative pancreatic leaks and overall morbidity.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
Researchers have designed a candidate drug to target the K-Ras G12D mutation, responsible for nearly half of all pancreatic cancer cases. The molecule permanently modifies the mutation, stopping tumor growth in cancer cell lines and animal models.
Researchers at Cold Spring Harbor Laboratory have uncovered a mechanism involved in pancreatic cancer transformation, discovering that low-grade pancreatic cancer cells depend on mucus to survive and thrive. This knowledge could help set the stage for future diagnostic or therapeutic strategies.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
A University of Oklahoma researcher has made promising discoveries on the role of vitamin B6 in pancreatic cancer. By understanding how pancreatic cancer cells deplete vitamin B6, she developed a three-part strategy to impede their growth and enhance immune function.
A new off-the-shelf vaccine has shown promise in treating pancreatic and colorectal cancers in patients with KRAS mutations. The study found that the vaccine significantly decreased tumor biomarkers and produced strong T-cell responses, leading to a reduced risk of relapse and death.
New research led by Johns Hopkins Medicine reveals that age-related changes in fibroblast cells enable pancreatic cancer tumor growth. The study found that older patients have poorer prognoses due to altered proteins released by fibroblasts, which promote cancer cell growth and spread.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A study published in Oncotarget has identified specific mutational and therapeutic landscapes of pancreatic cancer in the Russian population. By applying machine learning models to full exome individual data, researchers received personalized recommendations for targeted treatment options for each clinical case.
Scientists have discovered that pancreatic cancer hijacks the brain-building protein Engrailed-1, leading to faster and deadlier metastasis. By targeting this aberrant protein, researchers may be able to develop personalized therapies and slow cancer progression.
Researchers discovered that blocking efferocytosis pathway prevents immunosuppressive activity in macrophages, restoring T cell activation and reducing metastatic tumour burden. The study found PDAC metastases to show high levels of immunosuppressive macrophages, promoting tumour growth.
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
A study published in Advanced Science identified Engrailed-1 as a key factor promoting pancreatic cancer progression and metastasis. The researchers found that elevated Engrailed-1 levels were associated with severe pancreatic cancer, suggesting it as a potential target for therapies.
Researchers at the University of Oklahoma Health Sciences have developed a new imaging technique that can detect pancreatic cancer cells approximately 10 times more magnificently than current options. The approach combines contrast agent recognition with Multispectral Optoacoustic Tomography, enabling real-time detection and surgery pl...
Experts predict a significant increase in bowel cancer death rates among young adults in the EU and UK, driven by rising obesity and heavy alcohol consumption. Death rates are predicted to rise by 26% in men and nearly 39% in women in the UK, with similar increases seen in Italy and other European countries.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
A study from Dana-Farber Cancer Institute found that unintentional weight loss is associated with an increased risk of cancer diagnosis within the coming year. The research suggests that patients experiencing unexpected weight loss should see their doctor to consider possible causes, including cancer. Healthy weight loss can come from ...
Researchers found that the loss of RBFOX2 protein leads to increased cell migration, invasion, tumor development, and metastasis in pancreatic cancer. The study suggests alternative RNA splicing plays a critical role in pancreatic cancer progression.
A Phase I trial demonstrated that a vaccine targeting KRAS mutations delayed relapse in patients with high-risk pancreatic and colorectal cancer. The vaccine induced significant T cell responses, which correlated with reduced risk of relapse.
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
A drug screening system modeling cancers with lab-grown tissues called organoids helped uncover a promising target for future pancreatic cancer treatments. Researchers identified an existing heart drug, perhexiline maleate, that powerfully suppresses the growth of pancreatic tumor organoids.
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...
Researchers found that secreted frizzled-related protein 2 (SFRP2) is abundantly expressed in pancreatic cancer, with higher levels linked to poorer outcomes. Blocking SFRP2 may affect tumor growth, angiogenesis, and the immune system, making it a potential therapeutic target.
Researchers confirm that pancreatic cancer triggers a response in the immune system, but T cells struggle to infiltrate tumors. This finding could guide future treatment development for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer.
Researchers developed a new radiation therapy approach combining a sensitizing drug with stereotactic body radiation therapy, resulting in higher progression-free survival and overall response rates. The treatment reduced toxicity while increasing its effectiveness in treating locally advanced pancreatic cancer.
Researchers have made a breakthrough in understanding the genetic changes that occur during tumor migration, and discovered a drug that can obstruct this process. A new clinical trial at the University of Rochester's Wilmot Cancer Institute will test the effectiveness of the experimental drug NP137.
A long-term study published in Environmental Epidemiology shows a slightly increased incidence of cancer, particularly colon, pancreas, and stomach cancer in men, as well as lymphoma in women. The researchers used new calculation methods to analyze radiation doses from Chernobyl fallout.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
A new model reveals how a single pool of stem and progenitor cells in the pancreas can give rise to multiple types of pancreatic cancer. The study suggests that understanding the cell from which a cancer arises can help researchers develop therapies tailored to an individual's disease.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
Researchers at Mainz University Medical Center aim to improve patients' quality of life by applying smart data technology to physical activity. The DECIDE project aims to provide individualized control of patients' daily physical activity, while the RELEVIUM project focuses on alleviating pain and weight loss in pancreatic cancer patie...
Researchers at University of British Columbia find a direct link between high insulin levels and pancreatic cancer, highlighting the importance of keeping insulin levels within a healthy range. The study suggests that excessive insulin overstimulates pancreatic acinar cells, leading to inflammation and precancerous cell development.
The partnership aims to reduce disparities in cancer research and drug development through collaborations, resources, and training programs. Key projects will focus on breast and pancreatic cancers, particularly luminal B breast cancers disproportionately affecting women of African descent.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
Researchers found amoeboid cells in pancreatic cancer produce CD73, which drives spread and weakens immune system. Blocking CD73 reduced cancer spread to liver and decreased immune cell support.
Researchers at Osaka University have developed a novel radioactive antibody that can diagnose and treat a deadly type of pancreatic cancer. The antibody targets glypican-1, a protein highly expressed in PDAC tumors, allowing for early detection and treatment with improved survival rates.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
Researchers have discovered a new mechanism for starving pancreatic cancer cells, potentially leading to improved treatment outcomes. A combination of treatments involving the drug DRP-104, which blocks glutamine metabolism, and trametinib, an existing ERK signaling pathway blocker, showed promising results in mouse models.
Researchers at Sanford Burnham Prebys have developed a new approach to treat pancreatic cancer by feeding tumors a copycat of the important nutrient glutamine. This method significantly slowed pancreatic tumor growth and prevented the spread of tumors in early clinical trials.
The study developed a highly accurate AI model for fully automated cancer detection, including small and difficult-to-detect tumors. The model could detect visually imperceptible cancer from normal-appearing pancreases substantially early before clinical diagnosis, with a median of 438 days.
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
Scientists have identified a DNA methylation pattern that can accurately diagnose pancreatic cancer, distinguishing it from chronic pancreatitis. The marker, which involves six specific methylation positions in the PRKCB gene, has been validated on tissue and blood samples, offering hope for improved diagnosis and treatment.
Researchers developed a reliable and reproducible real-time live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to predict patients' clinical response to chemotherapy. The study showed improved disease-free survival and reduced recurrence rates in patients who received RT-LTSA sensitive adjuvant regimens.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Researchers at MD Anderson successfully reduced inpatient opioid use by 50% and median prescription volumes to zero after pancreatic cancer surgery. This approach achieved effective pain control for patients without increasing the risk of opioid dependence.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.